Home | Job-opportunities | Contact | News | Donate
 S'abonner à DNDi_HQ sur Twitter 
Home Diseases Malaria DNDi Strategy

DNDi Strategy

Attention: open in a new window. PDFPrint


DNDi Strategy
 
DNDi’s malaria-specific portfolio aims to facilitate the widespread availability of the two products delivered by its diverse partners in the Fixed-Dose Artesunate Combination Therapy (FACT) Project. Because of numerous antimalarial R&D activities (eg. Medicines for Malaria Venture), DNDi is phasing out its malaria activities to focus on the kinetoplastid diseases.

The FACT Project has produced 2 fixed-dose ACTs which are:
– Easy to use as given in a single daily dose of 1 or 2 tablets for 3 days
– A 2-in-1 fixed-dose combination (FDC) of drugs that ensures both drugs are taken together and in correct proportions
– Age-based dosing to facilitate proper dosing in rural, remote areas

  • ASAQ – FDC of artesunate and amodiaquine for treatment of malaria in sub-Saharan Africa; now registered in 24 countries
  • ASMQ – FDC of artesunate and mefloquine registered in Brazil in March 2008 and in use by Brazilian national authorities as part of ongoing intervention study

To learn more about ASAQ
To learn more about ASMQ

Malaria



Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License